Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients
暂无分享,去创建一个
Thilo Dörk | Annegien Broeks | Heli Nevanlinna | Rainer Fagerholm | Carl Blomqvist | Mitul Shah | Douglas F Easton | T. Dörk | D. Easton | A. Broeks | P. Pharoah | H. Nevanlinna | R. Fagerholm | M. Shah | M. Schmidt | C. Blomqvist | M. Humphreys | F. V. van Leeuwen | Flora E van Leeuwen | Marjanka K Schmidt | Johanna Tommiska | Laura J Van't Veer | Paul DP Pharoah | Manjeet Humphreys | Scarlett A Reincke | Manjeet K. Humphreys | J. Tommiska | S. Reincke | L. V. van‘t Veer | L. V. van’t Veer
[1] David J. Hunter,et al. The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses’ health studies , 2006, Cancer Causes & Control.
[2] Genica,et al. Commonly studied single-nucleotide polymorphisms and breast cancer: Results from the Breast Cancer Association Consortium , 2006 .
[3] K Holli,et al. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. , 2000, Journal of the National Cancer Institute.
[4] Douglas G Altman,et al. Reporting recommendations for tumor marker prognostic studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] T. Dörk,et al. Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer , 2001, British Journal of Cancer.
[6] T. Dörk,et al. Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients. , 2001, Cancer research.
[7] A. Levine,et al. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[8] F. Penault-Llorca,et al. p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] T. Dörk,et al. Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. , 2007, Cancer research.
[10] Yuntao Xie,et al. p53 Codon 72 Polymorphism Predicts the Pathologic Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer , 2005, Clinical Cancer Research.
[11] T. Crook,et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo , 2004, Oncogene.
[12] J. Bergh,et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] L. Holmberg,et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. , 1996, Journal of the National Cancer Institute.
[14] J. Peterse,et al. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] B. Ponder,et al. Effect of germ-line genetic variation on breast cancer survival in a population-based study. , 2002, Cancer research.
[16] K. Soo,et al. Evidence for Selective Expression of the p53 Codon 72 Polymorphs: Implications in Cancer Development , 2005, Cancer Epidemiology Biomarkers & Prevention.
[17] C. Bonaïti‐pellié,et al. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome , 2005, Journal of Medical Genetics.
[18] Paul D.P. Pharoah,et al. Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. , 2007, Journal of the National Cancer Institute.
[19] J. Overgaard,et al. LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer , 2006, Acta oncologica.
[20] Peter Kraft,et al. Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics , 2008, PLoS genetics.
[21] H. Iwata,et al. Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients , 2007, Breast Cancer Research.
[22] A. Levine,et al. A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.
[23] D. Pim,et al. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression , 2004, International journal of cancer.
[24] Yuntao Xie,et al. Effect of p53 codon 72 genotype on breast cancer survival depends on p53 gene status , 2008, International journal of cancer.
[25] B. Ponder,et al. Genetic variants in epigenetic genes and breast cancer risk. , 2006, Carcinogenesis.
[26] A. Børresen-Dale,et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes , 2007, Oncogene.
[27] R. Greil,et al. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] L. Kadouri,et al. Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations , 2009, BMC Cancer.
[29] M. Zvelebil,et al. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72–polymorphic p53 , 2006, Nature Genetics.
[30] Päivi Heikkilä,et al. Breast Cancer Patients with p53 Pro72 Homozygous Genotype Have a Poorer Survival , 2005, Clinical Cancer Research.
[31] G. Prendergast,et al. The polyproline region of p53 is required to activate apoptosis but not growth arrest , 1997, Oncogene.
[32] M. Murphy,et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential , 2003, Nature Genetics.
[33] B. Gusterson,et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. , 2003, Cancer cell.
[34] Thierry Soussi,et al. Assessing TP53 status in human tumours to evaluate clinical outcome , 2001, Nature Reviews Cancer.
[35] Julie E Goodman,et al. Association of breast cancer outcome with status of p53 and MDM2 SNP309. , 2006, Journal of the National Cancer Institute.
[36] L. J. Veer,et al. The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li–Fraumeni syndrome and related phenotypes , 2007, European Journal of Human Genetics.
[37] Miranda Thomas,et al. Two Polymorphic Variants of Wild-Type p53 Differ Biochemically and Biologically , 1999, Molecular and Cellular Biology.
[38] C. Franceschi,et al. Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[39] J. Klijn,et al. MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling , 2007, Breast Cancer Research and Treatment.
[40] R. Schneider-Stock,et al. Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. , 2004, The American journal of pathology.
[41] Jacqueline Lehmann,et al. TP53 Status and Response to Chemotherapy in Breast Cancer , 2008, Pathobiology.
[42] Päivi Heikkilä,et al. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer , 2008, Nature Genetics.
[43] A. Levine,et al. MDM2 is a central node in the p53 pathway: 12 years and counting. , 2005, Current cancer drug targets.